John Fleming - USANA Health Independent Director
| USNA Stock | USD 39.16 1.12 2.94% |
Director
John Fleming is Independent Director of USANA Health Sciences since 2020.
| Age | 77 |
| Tenure | 4 years |
| Phone | 801 954 7100 |
| Web | https://www.usana.com |
John Fleming Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Fleming against USANA Health stock is an integral part of due diligence when investing in USANA Health. John Fleming insider activity provides valuable insight into whether USANA Health is net buyers or sellers over its current business cycle. Note, USANA Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell USANA Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Fleming over three months ago Disposition of 1000 shares by John Fleming of USANA Health at 44.43 subject to Rule 16b-3 |
USANA Health Management Efficiency
The company has return on total asset (ROA) of 0.0809 % which means that it generated a profit of $0.0809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1083 %, meaning that it created $0.1083 on every $100 dollars invested by stockholders. USANA Health's management efficiency ratios could be used to measure how well USANA Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Travis Robbins | Bridgford Foods | N/A | |
| Ellen Harshman | Post Holdings | 75 | |
| Matthew Rubel | Treehouse Foods | 62 | |
| David Skarie | Post Holdings | 74 | |
| Robert Grote | Post Holdings | 77 | |
| Linda Massman | Treehouse Foods | 53 | |
| Gregory Curl | Post Holdings | 71 | |
| David Vermylen | Treehouse Foods | 69 | |
| Jean Spence | Treehouse Foods | 62 | |
| Frank OConnell | Treehouse Foods | 76 | |
| Raymond Lancy | Bridgford Foods | 70 | |
| David Kemper | Post Holdings | 70 | |
| Mary Springer | Central Garden Pet | 60 | |
| Edwin Callison | Post Holdings | 65 | |
| John Hanson | Central Garden Pet | 58 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0809 |
USANA Health Sciences Leadership Team
Elected by the shareholders, the USANA Health's board of directors comprises two types of representatives: USANA Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of USANA. The board's role is to monitor USANA Health's management team and ensure that shareholders' interests are well served. USANA Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, USANA Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Wood, Independent Director | ||
| Andrew Masuda, Director Relations | ||
| Patrique Richards, Executive Development | ||
| Paul Jones, CFO, Principal Accounting Officer and Chief Leadership Devel. Officer | ||
| Peggie Pelosi, Independent Director | ||
| Frederic Winssinger, Independent Director | ||
| Joshua Foukas, General Officer | ||
| Peter Benedict, Chief Officer | ||
| Douglas Hekking, Chief Officer | ||
| John Cuomo, Executive Technology | ||
| Walter Noot, Chief Operating Officer | ||
| Brian Dixon, Executive Education | ||
| P Foukas, Chief Legal Officer, General Counsel and Corporate Secretary | ||
| Feng Peng, Independent Director | ||
| Kevin Guest, Chairman of the Board, Chief Executive Officer | ||
| Xia Ding, Independent Director | ||
| Daniel Macuga, Chief Communications and Marketing Officer | ||
| Robert Anciaux, Independent Director | ||
| David Mulham, Chief Field Development Officer | ||
| Gilbert Fuller, Lead Independent Director | ||
| Myron Wentz, Founder and Chairman | ||
| John Fleming, Independent Director | ||
| Joshua JD, General Officer | ||
| Jim Brown, Chief Production Officer | ||
| Brent Neidig, Chief Officer and Managing Director of China | ||
| G Hekking, Chief Financial Officer | ||
| Robert Sinnott, Chief Scientific Officer | ||
| Dr MNS, Chief Officer |
USANA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is USANA Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0809 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 419.36 M | ||||
| Shares Outstanding | 19.06 M | ||||
| Shares Owned By Insiders | 41.70 % | ||||
| Shares Owned By Institutions | 57.61 % | ||||
| Number Of Shares Shorted | 504.83 K | ||||
| Price To Earning | 8.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether USANA Health Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of USANA Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Usana Health Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Usana Health Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of USANA Health. If investors know USANA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about USANA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of USANA Health Sciences is measured differently than its book value, which is the value of USANA that is recorded on the company's balance sheet. Investors also form their own opinion of USANA Health's value that differs from its market value or its book value, called intrinsic value, which is USANA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because USANA Health's market value can be influenced by many factors that don't directly affect USANA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between USANA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if USANA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, USANA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.